Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antox in Immune Thrombocytopenia
NCT01763658Phase 3Unknown
- Sponsor
- Ain Shams University
- Start
- Mar 2013
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Antox in immune thrombocytopenia (ITP) (2 arms), sponsored by Ain Shams University. Primary endpoint: oxidant status in ITP at 6 months. Status: unknown.
02
Drugs
Antox
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT01763658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01763658.